Literature DB >> 3530435

Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas.

E L Friedman, D F Hayes, D W Kufe.   

Abstract

We have previously described the monoclonal antibody (MAb) DF3, prepared against a human breast carcinoma. MAb DF3 reacts with a high molecular weight glycoprotein detectable in human breast carcinomas and in human milk. Previous studies have demonstrated that DF3 antigen levels are elevated in the plasma of patients with breast and ovarian cancer. The present study has further examined the reactivity of MAb DF3 with human ovarian carcinomas. Immunoperoxidase staining demonstrated reactivity of MAb DF3 with 95% of benign, borderline, and malignant tumors (serous, mucinous, and endometrioid) of the ovary. Furthermore, malignant tumors contained cytoplasmic DF3 antigen while benign tumors expressed the antigen only on apical surfaces. Western blot analyses demonstrated that the MAb DF3 reactive ovarian antigen (DF3-O) was a glycoprotein with a heterogenous molecular weight ranging between 300,000 and 450,000. This antigen was detectable by immunofluorescence on the cell surface of five of six cultured human ovarian carcinoma cell lines. The extent of cell surface reactivity with MAb DF3 was equivalent to or greater than that obtained with MAb OC125, an antibody generated against coelomic epithelium and developmental amnion. Furthermore, uptake of 125I-labeled MAb DF3 by human ovarian carcinoma xenografts in athymic mice was 5.4- and 6.2-fold higher than the respective uptake noted in liver and control tumor (P = 0.031). These findings suggest that DF3-O antigen is similar if not identical to the antigen detected in human breast carcinomas by MAb DF3. Thus, MAb DF3 may be a useful reagent in immunodiagnostic evaluation of patients with ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3530435

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

Authors:  T Kurihara; D E Brough; I Kovesdi; D W Kufe
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

2.  Polymorphic expression of a human superficial bladder tumor antigen defined by mouse monoclonal antibodies.

Authors:  Y Fradet; N Islam; L Boucher; C Parent-Vaugeois; M Tardif
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

3.  Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources.

Authors:  L Chen; M Pulsipher; D Chen; C Sieff; A Elias; H A Fine; D W Kufe
Journal:  J Clin Invest       Date:  1996-12-01       Impact factor: 14.808

4.  Regulation of herpes simplex virus 1 replication using tumor-associated promoters.

Authors:  John T Mullen; Hideki Kasuya; Sam S Yoon; Nancy M Carroll; Timothy M Pawlik; Soundararajalu Chandrasekhar; Hideo Nakamura; James M Donahue; Kenneth K Tanabe
Journal:  Ann Surg       Date:  2002-10       Impact factor: 12.969

5.  Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen.

Authors:  J Siddiqui; M Abe; D Hayes; E Shani; E Yunis; D Kufe
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

6.  Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin.

Authors:  Y Li; A Bharti; D Chen; J Gong; D Kufe
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

Review 7.  Conditionally replicating adenoviruses for cancer treatment.

Authors:  Youssef Jounaidi; Joshua C Doloff; David J Waxman
Journal:  Curr Cancer Drug Targets       Date:  2007-05       Impact factor: 3.428

8.  Serum levels and biochemical characteristics of human ovarian carcinoma-associated antigen defined by murine monoclonal antibody, CF511.

Authors:  K Ohkawa; Y Tsukada; M Murae; E Kimura; K Takada; T Abe; Y Terashima; K Mitani
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640

9.  The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.

Authors:  Elizabeth S Gabitzsch; Kwong Yok Tsang; Claudia Palena; Justin M David; Massimo Fantini; Anna Kwilas; Adrian E Rice; Yvette Latchman; James W Hodge; James L Gulley; Ravi A Madan; Christopher R Heery; Joseph P Balint; Frank R Jones; Jeffrey Schlom
Journal:  Oncotarget       Date:  2015-10-13

10.  Circulating CA 15-3 antigen levels in non-mammary malignancies.

Authors:  R Colomer; A Ruibal; J Genollà; L Salvador
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.